Acute myeloid leukaemia recurrent

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
6 Unique sponsors
8 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 2
M Musculoskeletal (ATC M) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
BCL-2 inhibitor 1 substance
Antimetabolite 1 substance
Phase I/II: 2 Phase I: 2 Phase I (First in Human): 2

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase I/II

2 trials
  • Aop Orphan Pharmaceuticals GmbH Commercial
    LB-208
    2025-523396-38-00 1 country n=60
    Pending
  • Stelexis Biosciences Inc. Commercial
    CYTARABINE; EGANELISIB
    2024-518071-58-00 1 country 2025 n=19
    Recruiting

Phase I

2 trials
  • Celgene Corp. Commercial
    IMP not specified
    2022-500573-13-00 1 country 2021 n=22
    Ended
  • Institut Paoli Calmettes Academic
    IMP not specified
    2024-518265-10-01 1 country 2020 n=24
    Ended

Phase I (First in Human)

2 trials
  • AstraZeneca AB Commercial
    AZD3632
    2025-521299-76-00 3 countries 2025 n=17
    Recruiting
  • Institut De Recherches Internationales Servier IRIS Commercial
    ALLOPURINOL; RASBURICASE; S227928; VENETOCLAX
    2024-514356-33-00 3 countries 2025 n=54
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase I (First in Human) 1
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I (First in Human) 0
Aop Orphan Pharmaceuticals GmbH Commercial 1 Phase I/II 0
Stelexis Biosciences Inc. Commercial 1 Phase I/II 1
Institut Paoli Calmettes Academic 1 Phase I 0
New trials by year
2020
1
2021
1
2025
3
← All indication landscapes